Marit Aarønæs, Dan Atar, Vernon Bonarjee, Torstein Gundersen, Maja-Lisa Løchen, Rune Mo, Eivind S.P. Myhre, Torbjørn Omland, Per K. Rønnevik, Johnny Vegsundvåg, Arne Westheim
Norsk cardiologisk selskaps arbeidsgruppe for hjertesvikt
()
Hovedbudskap
ACE-hemmere og diuretika er førstevalg ved behandling av kronisk hjertesvikt, men dersom ACE-hemmere ikke tolereres, kan AII-antagonister institueres
Betablokkere skal vurderes hos alle med symptomatisk hjertesvikt
Det er viktig å monitorere nyrefunksjon og elektrolyttnivå, spesielt hos eldre
Mekanisk behandling med biventrikulær pacemaker og hjertestarter kan være aktuelt for selekterte pasienter
For pasienter med kronisk hjertesvikt er det viktig med god og organisert omsorg på flere nivåer i behandlingskjeden og med flere yrkesgrupper involvert
1.
Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397 – 402.
2.
Westheim A, Dickstein K, Gundersen T et al. Kronisk hjertesvikt – forslag til handlingsprogram. Tidsskr Nor Lægeforen 1999; 119: 3427 – 31.
3.
Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115 – 40.
4.
Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm society. Circulation 2005; 112: e154 – 235.
5.
Larsen AI, Dickstein K. Exercise training in congestive heart failure. A review of the current status. Minerva Cardioangiol 2005; 53: 275 – 86.
6.
Feenstra J, Grobbee DE, Remme WJ et al. Drug-induced heart failure. J Am Coll Cardiol 1999; 33: 1152 – 62.
7.
Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur J Heart Fail 2000; 2: 229 – 33.
8.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429 – 35.
9.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821 – 8.
10.
Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575 – 81.
11.
Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487 – 96.
12.
Faris R, Flather M, Purcell H et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002; 82: 149 – 58.
13.
Dulin BR, Krum H. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 2006; 21: 393 – 9.
14.
Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 2005; 95: 14B – 23B.
15.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001 – 7.
16.
Cleland JG, Goode K, Erhardt L et al. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther 2004; 18: 139 – 52.
17.
Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7 – 13.
18.
Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426 – 35.
19.
Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582 – 7.
20.
Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110: 2618 – 26.
21.
Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777 – 81.
22.
Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709 – 17.
23.
Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309 – 21.
24.
Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425 – 31.
25.
Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871 – 8.
26.
O’Connor CM, Carson PE, Miller AB et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998; 82: 881 – 7.
27.
Cleland JG, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J 1996; 17: 674 – 81.
28.
Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920 – 5.
29.
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350: 1417 – 24.
30.
Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877 – 83.
31.
Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539 – 49.
32.
Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2000; 6: 276 – 85.
33.
Silverberg DS, Wexler D, Blum M et al. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003; 60 (suppl 1): S93 – 102.
34.
Wexler D, Silverberg D, Blum M et al. Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant 2005; 20 (suppl 7): vii11 – vii15.
35.
Cleland JG, Nikitin N, McGowan J. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc Ther 2004; 2: 9 – 19.
36.
Gheorghiade M, Gattis WA, O"Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963 – 71.
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
Publisert: 18. januar 2007
Utgave 2, 18. januar 2007
Tidsskr Nor Lægeforen 18. januar 2007
Manuskriptet ble mottatt 23.6. 2006 og godkjent 17.10. 2006. Medisinsk redaktør Petter Gjersvik.
127
:
174-7
Publisert:
18. januar 2007
Utgave 2, 18. januar 2007
Tidsskr Nor Lægeforen 2007
127
:
174-7
Manuskriptet ble mottatt 23.6. 2006 og godkjent 17.10. 2006. Medisinsk redaktør Petter Gjersvik.
Får du ikke vist PDF-filen eller vil lagre filen, kan du høyreklikke på PDF-ikonet. Velg «Lagre mål/fil som..» og hent så opp PDF-filen i for eksempel Acrobat Reader.